GeneralConnection.com ➔ Dictionary
Dictionary Search

haemophilia b

Synonyms

Noun

1. hemophilia B

2. haemophilia B, Christmas disease, hemophilia, haemophilia, bleeder's disease

Usage
CSL Canada Announces First Canadian Patient Receives HEMGENIX® (etranacogene dezaparvovec) Hemophilia B Gene Therapy in Ontario, Canada – Company Announcement - FT.com - Financial Times
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
How durable is gene therapy for haemophilia B? - Nature
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Gene therapy can help reduce joint bleeds in hemophilia B: New data - Hemophilia News Today
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors - Business Wire
Building safeguards for gene therapy in haemophilia - The Lancet
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Pfizer receives EC approval for Hympavzi to treat haemophilia - Yahoo
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Marstacimab Superior to On-Demand Prophylaxis for Hemophilia A, B, With Inhibitors - Docwire News
New gene therapy reduces bleeding rates for hemophilia B patients - Hemophilia News Today
Exploring gene editing as a potential therapeutic strategy for hemophilia - Frontiers
4 Things to Expect for the Future of Hemophilia Treatment - Docwire News
Exploring Eptacog Beta Dosing in Patients With Hemophilia A or B - Docwire News
Patients With Hemophilia Face Significant Burden Despite Treatment Type or Disease Severity - Docwire News
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Marstacimab in the treatment of patients with hemophilia A and B - Via Medica Journals
Redefining Hemophilia Management: Treatment Goals, Nonfactor Replacement Therapies, and the Role of Fitusiran - AJMC
Phase 3 Analysis: Concizumab Noninferior to Prior Prophylaxis in Hemophilia A, B, Without Inhibitors - Docwire News
Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients - PMLiVE
AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
(marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need - Business Wire
Wolfgang Miesbach: New Study on AAV5 Antibodies in Haemophilia B Gene Therapy - Oncodaily
First German haemophilia B patient receives gene therapy HEMGENIX - PharmaTimes
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors - Business Wire
First-in-human trial of hemophilia B treatment BE-101 starts dosing - Hemophilia News Today
Netherlands Temporarily Includes Hympavzi in Basic Package for Hemophilia A & B - NAVLIN DAILY
Hemophilia B gene therapy benefits last more than a decade: Study - Hemophilia News Today
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Hull teenager first to be treated with new haemophilia drug - BBC
Fidanacogene Elaparvovec for Hemophilia B — A Multiyear Follow-up Study - The New England Journal of Medicine
Alhemo Indication Expanded to Include Hemophilia A/B Without Inhibitors - Medical Professionals Reference
FDA approves Alhemo® as once-daily prophylactic treatment to prevent or reduce the frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B (HA/HB) without inhibitors - PR Newswire
Nonfactor Therapies for Hemophilia: Current Evidence, Clinical Relevance and Cost Considerations - Managed Healthcare Executive
NICE recommends weekly injection for severe haemophilia B - The Pharmaceutical Journal
FDA Grants Priority Review For Pfizer’s Marstacimab for Hemophilia A or B - PharmTech.com
China Explores Weight-Based Pricing for First Domestic Hemophilia B Gene Therapy - NAVLIN DAILY
Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use - PMLiVE
Extended hemophilia half-life products aid care, but raise costs - Hemophilia News Today
Hemophilia gene therapy: A new era of treatment and the obstacles ahead - Drug Discovery News
Haemophilia gene therapy patients thriving over a decade after treatment | UCL News - UCL - UCL | University College London
Spotlight on the ISTH Hemophilia Treatment Guidelines and Alternate Recommendations - Hematology Advisor
One dose of gene therapy gives years of relief from blood disorder - Nature
Hemophilia prognosis: Life expectancy and outlook - Hemophilia News Today
G-BA Rates “Considerable” Added Benefit of Alhemo for Hemophilia B Patients - NAVLIN DAILY
Pfizer reports positive results from Phase III BASIS trial for haemophilia - Clinical Trials Arena
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
How Fitusiran Changes the Treatment Landscape in Hemophilia: Guy Young, MD - AJMC
EVOLVING THE TREATMENT LANDSCAPE WITH THE FIRST THERAPY APPROVED FOR PEOPLE WITH HEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS - AJMC
Concizumab approved to prevent or reduce the frequency of bleeding episodes in people aged 12 years and older with haemophilia A or B with inhibitors - GOV.UK
FDA expands approvals for Novartis lipid drug, Novo haemophilia prophylatic - FirstWord Pharma
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors - BioSpace
CSL’s haemophilia therapy shows durable five-year benefits in landmark trial results - BiotechDispatch
First Patient in Germany Treated With Hemgenix for Hemophilia B - NAVLIN DAILY
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
How pioneering gene therapy changed the life of the first man in Wales to receive it - Nation.Cymru
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
Lighting up the library for World Haemophilia Day 2026 - Birmingham City Council
Haemophilia A vs B: Which is more severe? Here’s what sets them apart - TheHealthSite
Pfizer sets up Hympavzi expansion into haemophilia A or B with inhibitors - FirstWord Pharma
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B - The New England Journal of Medicine
With hemophilia B, a lifetime of worry eased with one infusion - Penn Today
CSL Behring treats two patients with gene therapy for haemophilia B - Clinical Trials Arena
NMPA approves BBM and Takeda China’s haemophilia B therapy - Pharmaceutical Technology
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
Non-replacement therapy for people with haemophilia B: another step towards health equity - The Lancet
First NHS patient given world's most expensive drug that costs £2.6 million per dose - LADbible
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years - Mynewsdesk
Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system - Nature
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
Groundbreaking treatment for haemophilia administered in Wales for first time - Nation.Cymru
Why Hympavzi Secured English Funding For Hemophilia B But Not Hemophilia A - Citeline News & Insights
Belief, Takeda’s home-grown haemophilia B gene therapy gains nod in China - FirstWord Pharma
Transformational therapy cures haemophilia B - BBC
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B - PR Newswire Canada
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice - Nature
Real Stories from People Living with Hemophilia - Centers for Disease Control and Prevention | CDC (.gov)
UK Approves Marstacimab for Severe Haemophilia A or B - Medscape
Haemophilia - The Lancet
Haemophilia injections hailed as ‘real step forward’ for sufferers - STV News
Gene Therapy for Hemophilia B Could Lower Health Plans’ Budget Over Time - AJMC
uniQure announces FDA approval of first gene therapy for adults with hemophilia B - uniqure.gcs-web.com
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
Articles that Use Data from Community Counts - Centers for Disease Control and Prevention | CDC (.gov)
‘A game-changer for our son’: City teen first in UK to be treated with new haemophilia drug - The Hull Story
An Observational Study of Glycopegylated Extended Half-Life Factor Prophylaxis in Hemophilia A and B in a Tertiary Care Center in India - Cureus
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
$3.5-Million Hemophilia Gene Therapy Is World’s Most Expensive Drug - Scientific American
FDA Approves One-Time Gene Therapy Fidanacogene Elaparvovec for Hemophilia B - AJMC
Foreign Language Equivalents
Foreign Language Equivalents of 'haemophilia b'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
aemophilia b,   haemopihlia b,   haaemophilia b,   haemophiliab ,   haemiphilia b,   haemopgilia b,   haemo[hilia b,   haemophhilia b,   hawmophilia b,   haemoohilia b,   ahemophilia b,   haemophiila b,   haeomphilia b,   haeophilia b,   jaemophilia b,   haemopilia b,   haenophilia b,   haemopholia b,   haemophila b,   hamophilia b,   haemophikia b,   haemohilia b,   haemmophilia b,   heamophilia b,   haemopjilia b,   haemophiliab,   haemophulia b,   haempphilia b,   haemophilia b,   haemoophilia b,   haemophilia ,   haemophillia b,   haemophilua b,   haemophilis b,   hameophilia b,   hsemophilia b,   haemophiia b,   haemophlia b,   haemophiliia b,   hae,ophilia b,   haempohilia b,   gaemophilia b,   haemophilia v,   haemophliia b,   haemohpilia b,   haemophilai b,   hemophilia b,   haemophi;ia b,   haeemophilia b,   haemophilia bb,   haemophiliaa b,   haemophili ab,   hhaemophilia b,   haemophiloa b,   haemophiilia b,   haemophili b,   haemophilia n,   haemopphilia b,   harmophilia b,   haemphilia b
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z